Myriad Genetics Inc. Common Stock
MYGNUnited States
5 filed reports · 234 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 868 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 776 | Dec 2025 |
Financial data
234 concepts · 1,644 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial231 concepts · 1,492 facts · Nov 2023 to Jun 2026
- Stockholders equity (US GAAP)14 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value13 · Dec 2023 to Jun 2026
- Cash and cash equivalents at carrying value13 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
- Common stock shares issued13 · Dec 2023 to Jun 2026
- Common stock shares outstanding13 · Dec 2023 to Jun 2026
- Net income loss13 · Dec 2023 to Jun 2026
- Restricted cash13 · Dec 2023 to Jun 2026
- Stock issued during period value share based compensation13 · Dec 2023 to Jun 2026
- Amortization of intangible assets12 · Dec 2023 to Jun 2026
- Comprehensive income net of tax12 · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)12 · Dec 2023 to Jun 2026
- Depreciation12 · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)12 · Dec 2023 to Jun 2026
- Goodwill and intangible asset impairment12 · Dec 2023 to Jun 2026
- Gross profit (US GAAP)12 · Dec 2023 to Jun 2026
- Income tax expense benefit12 · Dec 2023 to Jun 2026
- Interest expense nonoperating12 · Dec 2023 to Jun 2026
- Investment income interest12 · Dec 2023 to Jun 2026
- Nonoperating income expense12 · Dec 2023 to Jun 2026
- Operating expenses (US GAAP)12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax12 · Dec 2023 to Jun 2026
- Other nonoperating income expense12 · Dec 2023 to Jun 2026
Product1 concepts · 126 facts · Dec 2023 to Jun 2026
- Revenue126 · Dec 2023 to Jun 2026
Geography2 concepts · 26 facts · Dec 2023 to Jun 2026
- Revenue24 · Dec 2023 to Jun 2026
- Tenant improvement allowance not yet received2 · Mar 2026 to Jun 2026
Segments
152 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service9 members · 126 facts
- Tumor Profiling27 · Dec 2023 to Dec 2025
- Mental Health21 · Dec 2023 to Jun 2026
- Cancer Care Continuum12 · Mar 2025 to Jun 2026
- Hereditary Cancer Testing12 · Jun 2024 to Sep 2025
- Pharmacogenomics12 · Jun 2024 to Sep 2025
- Prenatal Health12 · Mar 2025 to Jun 2026
- Prenatal Testing12 · Jun 2024 to Sep 2025
- Hereditary Cancer9 · Dec 2023 to Dec 2025
- Prenatal9 · Dec 2023 to Dec 2025
Statement geographical3 members · 26 facts
- Non Us12 · Dec 2023 to Jun 2026
- US12 · Dec 2023 to Jun 2026
- West Salt Lake City2 · Mar 2026 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Aug 2025 to May 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q1May 5, 2026
- FY2025 Q4Feb 23, 2026
- FY2025 Q3Nov 3, 2025
- FY2025 Q2Aug 6, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.